Xiralite in Psoriatic Arthritis for longitudinal measurement of clinical activity using standardized biologic treatment
Recruiting
- Conditions
- L40.5L40.0Arthropathic psoriasisPsoriasis vulgaris
- Registration Number
- DRKS00006000
- Lead Sponsor
- Fraunhofer IMEProjektgruppe TMPc/o Universitätsklinikum Frankurt/Main
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
patients with active psoriatic arthritis, in Routine care planned Etanercept-therapy
Exclusion Criteria
Sensibility to contrast agents, esp. ICG, wounded hands, allergy to iodine, hyperthyreosis, adenoma of the thyroid, focal or diffuse autonomy of thyroid, significant co-morbidity or uncontrolled disease that influences patients safety
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Comparison of positive values of fluorescence-optical imaging to physical examination and ultrasound at baseline, week 4, week 12, week 24, week 36 and week 54.
- Secondary Outcome Measures
Name Time Method Comparison of fluorescence-optical imaging, physical examination and ultrasound